Patents by Inventor Kuo-Ping CHAO

Kuo-Ping CHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of osthole for treating focal segmental glomerulosclerosis
    Patent number: 9393226
    Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 19, 2016
    Assignee: National Defense Medical Center
    Inventors: Shuk-Man Ka, Ann Chen, Kuo-Feng Hua, Kuo-Ping Chao, Shun-Min Yang
  • Use of hydroxycinnamaldehyde glycoside derivatives for treating glomerulonephritis
    Patent number: 9321795
    Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 26, 2016
    Assignee: National Defense Medical Center
    Inventors: Ann Chen, Shuk-Man Ka, Kuo-Feng Hua, Shui-Tein Chen, Kuo-Ping Chao
  • USE OF OSTHOLE FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20150297560
    Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.
    Type: Application
    Filed: April 22, 2015
    Publication date: October 22, 2015
    Inventors: Shuk-Man KA, Ann CHEN, Kuo-Feng HUA, Kuo-Ping CHAO, Shun-Min YANG
  • USE OF HYDROXYCINNAMALDEHYDE GLYCOSIDE DERIVATIVES FOR TREATING GLOMERULONEPHRITIS
    Publication number: 20150299242
    Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.
    Type: Application
    Filed: April 22, 2015
    Publication date: October 22, 2015
    Inventors: Ann CHEN, Shuk-Man KA, Kuo-Feng HUA, Shui-Tein Chen, Kuo-Ping CHAO
  • Use of citral for treating focal segmental glomerulosclerosis
    Patent number: 8993637
    Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: March 31, 2015
    Assignee: National Defense Medical Center
    Inventors: Ann Chen, Kuo-Feng Hua, Shuk-Man Ka, Kuo-Ping Chao, Wen-Liang Chang, Kuo-Yuan Hwa
  • USE OF CITRAL FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20140343167
    Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.
    Type: Application
    Filed: April 11, 2014
    Publication date: November 20, 2014
    Applicant: National Defense Medical Center
    Inventors: Ann CHEN, Kuo-Feng HUA, Shuk-Man KA, Kuo-Ping CHAO, Wen-Liang CHANG, Kuo-Yuan HWA